Skip to main content

Table 2 Rates of clinical progression across NIA-AA preclinical AD stages

From: Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis

Reference Cohort Group N Clinical progression Mean follow-up (years) Stage 0, % (n progr/n tot) Stage 1, %
(n progr/n tot)
Stage 2, %
(n progr/n tot)
Stage 3, %
(n progr/n tot)
Eckerström et al., 2017 [72] Gothenburg MCI Study CN 113 Cognitive decline–dementiaa 4 28% (13/46) 50% (5/10) 81% (17/21) 100% (6/6)
Edmonds et al., 2015 [11] ADNI CN 570 MCI–dementiab 2.7 18% (25/142) 21% (10/48) 37% (64/173) 90% (45/50)
Knopman et al., 2012 [73] MCSA CN 296 MCI–dementiab 1.3 5% (6/127) 11% (5/44) 21% (8/39) 43% (3/7)
Soldan et al., 2016 [26] BIOCARD CN 222 MCI–dementiab 10.4 18% (18/102) 19.520% (9/46) 54% (15/28) Not specifically addressed
Van Harten et al., 2013 [95] Amsterdam Dementia Cohort SMC 132 MCI–dementiab 1.5 3% (2/80) 18% (2/11) 60% (6/10) Not specifically addressed
Vos et al., 2013 [62] WU-ADRC CN 311 MCIc 3.4 2% (2/129) 13% (6/47) 25% (9/36) 54% (7/13)
  1. AD Alzheimer’s disease, ADNI Alzheimer’s Disease Neuroimaging Initiative, BIOCARD Biomarkers of Cognitive Decline Among Normal Individuals, CN cognitively normal, MCI mild cognitive impairment, MCSA Mayo Clinic Study of Aging, NIA-AA National Institute on Aging and Alzheimer’s Association, SMC subjective memory complaints, n progr/n tot number progressed/total number, WU-ADRC Washington University Alzheimer’s Disease Research Center
  2. aCognitive decline outcome defined as decline in neuropsychological test results or to clinical dementia (using Global Deterioration Scale and criteria for dementia), at follow-up
  3. bProgression to diagnosis of MCI and dementia due to AD (NIA-AA criteria)
  4. cProgression to Clinical Dementia Rating Scale of at least 0.5 (MCI), symptomatic AD (score of at least 0.5 for memory and at least one other domain and cognitive impairments deemed to be due to AD)